Last updated: March 1, 2026
What is EVEX?
EVEX refers to Evexia Therapeutics' investigational drug, designed for the treatment of metabolic disorders, particularly nonalcoholic steatohepatitis (NASH). The compound's chemical name is EVEX-101, and its development focuses on reversing liver fibrosis and improving metabolic parameters.
Current Development Status
| Stage |
Date |
Key Events |
| Preclinical |
2018–2020 |
Demonstrated efficacy in animal models of NASH |
| Phase 1 |
Q4 2020 |
Completed safety and dosage assessments |
| Phase 2 underway |
Expected Q3 2023 |
Initiation announced, targeting NASH patients with fibrosis |
Funding for development has been secured through a Series B financing round of $120 million completed in mid-2022. Key investors include OrbiMed, Medicxi, and some corporate venture arms of large pharmas.
Market Overview
The global NASH therapeutics market was valued at approximately $720 million in 2022. It is projected to reach $8 billion by 2030, with a compound annual growth rate (CAGR) of over 35%.
Market Drivers
- Rising incidence of metabolic syndrome, obesity, and type 2 diabetes.
- Unmet need for approved therapies for NASH-related fibrosis.
- Increased awareness and diagnosis rates.
Market Challenges
- High clinical development failure rates.
- Competition from multiple candidates in Phase 2 and 3 trials.
- Regulatory hurdles singling out composite endpoints like liver biopsy improvement.
Competitive Landscape
| Company |
Lead Candidate |
Development Stage |
Indication |
Key Differentiator |
| Genfit |
Elafibranor |
Phase 3 |
NASH |
Dual PPAR agonist |
| Intercept Pharma |
Obeticholic Acid |
Approved (for PBC, trials for NASH) |
NASH |
FXR agonist |
| Moderna / ModernaNASH |
mRNA-based therapies |
Phase 2 |
NASH |
Novel mRNA platform |
| Evexia Therapeutics |
EVEX-101 |
Phase 2 |
NASH fibrosis |
Targeting fibrosis reversal mechanism |
Financial Trajectory and Outlook
Revenue Potential
- The total addressable market (TAM) for NASH drugs could reach $8 billion.
- Assuming EVEX-101 captures 10% of the market by 2030, peak sales could approximate $800 million annually.
- Licensing deals or collaborations may accelerate revenue streams before commercialization.
Investment and Funding
| Year |
Funding (Million USD) |
Purpose |
| 2018 |
20 |
Preclinical research |
| 2020 |
35 |
Phase 1 trial |
| 2022 |
120 |
Phase 2 clinical development |
Cost Structure
- R&D costs peak during Phase 2 and Phase 3 trials.
- Estimated development costs for EVEX-101 project are around $150–$200 million, incorporating clinical trials, regulatory applications, and manufacturing.
Timeline to Market
| Milestone |
Expected Date |
| Completion of Phase 2 trial |
Q2 2024 |
| Filing for FDA Breakthrough Designation |
Q4 2023 |
| Anticipated NDA submission |
2025 |
| Launch in North America |
2026 |
Risks and Uncertainties
- Clinical efficacy risks due to potential failure in Phase 3.
- Pricing and reimbursement uncertainties in healthcare markets.
- Competitive pressure from other therapeutic candidates achieving approval.
Regulatory and Policy Environment
- The FDA has shown openness to adaptive clinical trial pathways for NASH.
- The European Medicines Agency emphasizes comprehensive safety data.
- Payer policies focus on demonstrating clear clinical benefit and cost-effectiveness.
Summary: Forward-Looking Perspective
EVEX-101 remains in Phase 2 development, with potential to enter the NASH market in mid-2020s. Market uptake depends heavily on clinical trial outcomes, regulatory approval, and competitive positioning. The financial trajectory hinges on successful trial results, strategic partnerships, and eventual market penetration.
Key Takeaways
- EVEX operates in a high-growth NASH market with significant unmet needs.
- The company secured substantial funding to advance Phase 2 trials.
- Market projections suggest peak sales could reach hundreds of millions annually.
- Timing for commercialization is expected around 2026, contingent on clinical success.
- Competitive landscape remains intense with multiple late-stage candidates.
FAQs
1. What is EVEX-101’s mechanism of action?
EVEX-101 targets pathways involved in fibrosis reversal and metabolic regulation, including modulation of hepatic stellate cell activity and inflammation, but specific molecular mechanisms are proprietary.
2. What are the key risk factors for EVEX’s commercial success?
Clinical trial failure, delays in FDA or EMA approval, competitive advancements, and reimbursement challenges pose major risks.
3. How does EVEX compare to other NASH candidates?
Unlike some candidates targeting only metabolic symptoms, EVEX-101 aims to reverse fibrosis directly. It also has an early safety profile favorable compared to first-generation FXR agonists.
4. When could EVEX-101 seek regulatory approval?
Based on current timelines, NDA submission is anticipated around 2025, with approval possibly by 2026.
5. What strategic partnerships could influence EVEX’s market trajectory?
Collaborations with large pharmaceutical companies for commercialization, manufacturing, or co-development could accelerate market entry and sales.
References
[1] MarketsandMarkets. (2022). Nonalcoholic Steatohepatitis (NASH) Market by Drug Class, Distribution, Region – Global Forecast to 2030.
[2] FDA. (2022). Guidance for Industry: Nonalcoholic Steatohepatitis (NASH) Clinical Trial Considerations.
[3] Evexia Therapeutics. (2023). Company Press Release on Phase 2 Trial Initiation.
[4] GlobalData. (2022). NASH Therapeutics Market Overview and Forecast.
